Capture Bioscience Announces $749,999 in BARDA Funding to Advance Beads by Time-Of-Flight (B-TOF) Technology
Capture Bioscience, a pioneering company in innovative diagnostic technologies, has been awarded a contract worth $749,999 by the Division of Research, Innovation, and Ventures (DRIVe) of the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA), to further develop its Beads by Time-Of-Flight (B-TOF) technology. This funding will enable Capture Bioscience to continue establishing B-TOF’s capabilities towards commercialization for high-throughput multiplexed immune profiling, with applications to respiratory viruses and other pathogen-specific antibodies.
The funding will support the continued development of B-TOF, which uses bead-based serology combined with advanced mass spectrometry to provide comprehensive, immune profiling. The technology will expand its application to assess immune responses to a wide range of respiratory pathogens and refine new reagents and sample types for clinical and at-home sampling, enabling scalable and accessible diagnostics.
“Our B-TOF platform combines the power of bead-based serology with cutting-edge mass spectrometry, offering unmatched scalability and precision,” said David McIlwain, PhD, CEO and Co-Founder of Capture Bioscience. “This funding represents an important step toward enhancing public health preparedness by providing cost-effective and rapid diagnostic solutions that can be used for individual healthcare decisions as well as large-scale population monitoring.”
The B-TOF platform’s ability to assess multiple immune responses simultaneously addresses a critical gap in current diagnostics, which often rely on single-pathogen assays. With the capacity to process thousands of tests per assay, B-TOF significantly reduces costs, increases throughput, and accelerates immune profiling. The impact of this project will be profound, advancing vaccine efficacy studies, clinical decision-making, and global public health strategies.
About Capture Bioscience
Capture Bioscience is dedicated to advancing diagnostic technology to address global public health challenges. By leveraging advanced research and development, the company is pioneering new methods to assess immune responses and infectious disease dynamics. Capture Bioscience’s solutions are designed to be highly accurate, scalable, and accessible to diverse populations.
Contact:
David McIlwain, PhD - CEO
mcilwain@capturebioscience.com
+1 (650) 427-0783